Premium
Azatadine maleate in perennial allergic rhinitis: effects on clinical symptoms and choice reaction time.
Author(s) -
Hillas JL,
Somerfield SD,
Wilson JD,
Aman MG
Publication year - 1980
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1980.tb00513.x
Subject(s) - medicine , antihistamine , placebo , crossover study , intoxicative inhalant , allergy , histamine , anesthesia , sedative , dermatology , provocation test , immunology , toxicology , alternative medicine , pathology , biology
1 The efficacy of the antihistamine azatadine maleate at maximum recommended dosage (4 mg/day) for 1 week was assessed relative to placebo in a double‐blind crossover study of twenty patients with perennial allergic rhinitis. 2 Sixteen patients reported significant improvement in their clinical symptoms while taking the active drug. 3 The size of skin test weals for both histamine provocation and common inhalant allergens (prick test) diminished significantly after the azatadine treatment. There was no correlation between inhibition of skin reactions and symptom improvement. 4 Eight subjects reported sedative effects attributable to azatadine maleate. Their performance on a choice reaction to placebo occurred in the non‐sedated group.